Table S4.
Spectrophotometric analysis of Jurkat cell caspase activity after treatment with ZER-NLC
| Caspases | Cells (%)
|
|||||
|---|---|---|---|---|---|---|
| 24 hours
|
48 hours
|
72 hours
|
||||
| Control | ZER-NLC | Control | ZER-NLC | Control | ZER-NLC | |
| Caspase-8 | 0.05±0.01 | 0.058±0.003 | 0.056±0.004 | 0.063±0.003 | 0.061±0.003 | 0.068±0.003 |
| Caspase-3 | 0.06±0.003 | 0.13±0.01* | 0.09±0.003 | 0.199±0.007* | 0.1±0.1 | 0.221±0.01* |
| Caspase-9 | 0.065±0.001 | 0.151±0.016* | 0.071±0.002 | 0.211±0.012* | 0.086±0.001 | 0.261±0.011* |
Notes: Values are expressed as the mean ± standard deviation of three different experiments. The data were analyzed using post hoc comparison test-one way analysis of variance, with means compared by Tukey’s b test.
*
Significant (P<0.05) increase in caspase activity in the ZER-NLC-treated group versus untreated control.
Abbreviation: ZER-NLC, zerumbone-loaded nanostructured lipid carrier.